Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:43:06 EDT Tue 09 Jun 2026
Enter Symbol
or Name
USA
CA



Q:JAZZ - JAZZ PHARMACEUTICALS PLC - https://jazzpharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
JAZZ - Q0.1210.34·237.902.1232.04-6.53-2.71,208.5282,06916,539236.95  239.62  231.05243.32  105.0019:16:41Jun 0415 min RT 2¢

Recent Trades - Last 10 of 16539
Time ETExPriceChangeVolume
19:16:41Q231.2844-7.28561
19:08:03Q234.594-3.9765
16:26:44Q232.00-6.571
16:10:12Q233.9915-4.57855,300
16:10:04Q232.04-6.531
16:10:04Q232.04-6.531
16:10:04Q232.04-6.531
16:10:04Q232.04-6.531
16:10:04Q232.04-6.531
16:09:22Q232.04-6.5332,700

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-06-04 07:45U:JAZZNews ReleaseJazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia
2026-05-27 17:00U:JAZZNews ReleasePhase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera(TM) (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
2026-05-12 16:15U:JAZZNews ReleaseJazz Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-05-05 16:05U:JAZZNews ReleaseJazz Pharmaceuticals Announces First Quarter 2026 Financial Results
2026-04-27 07:45U:JAZZNews ReleaseJazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera(TM) (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
2026-04-21 16:15U:JAZZNews ReleaseJazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026
2026-04-21 16:05U:JAZZNews ReleaseJazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera(TM) (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca(TM) (lurbinectedin)
2026-04-09 07:45U:JAZZNews ReleaseJazz Pharmaceuticals to Present Research on Epidiolex(TM) (cannabidiol) and Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting
2026-04-01 16:15U:JAZZNews ReleaseJazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference
2026-03-24 13:49U:JAZZNews ReleaseAmerican Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education
2026-03-18 07:44U:JAZZNews ReleaseJazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
2026-02-24 16:05U:JAZZNews ReleaseJazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
2026-02-17 16:15U:JAZZNews ReleaseJazz Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-02-10 16:15U:JAZZNews ReleaseJazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026
2026-01-08 16:05U:JAZZNews ReleaseJazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer
2026-01-06 13:32U:JAZZNews ReleaseZiihera(TM) (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit
2025-12-17 16:15U:JAZZNews ReleaseJazz Pharmaceuticals to Participate in Upcoming Investor Events
2025-12-05 09:00U:JAZZNews ReleaseJazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex(TM) (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
2025-12-02 16:05U:JAZZNews ReleaseJazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera(TM) (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
2025-11-18 16:15U:JAZZNews ReleaseJazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference